Kornimate/medical-research-clean huggingface dataset:
extra-meso (exercise therapy in mesothelioma) feasibility

Conditions: Mesothelioma

Summary: the goal of this clinical trial is to learn whether running an exercise study in patients with mesothelioma is feasible. the main question(s) it aims to answer are: 1. is it feasible to recruit patients to a randomised clinical trial of exercise therapy 2. what are the barriers to study recruitment 3. what are the barriers to study retention participants who decide to take part in the study will be randomly allocated one of two study arms: 1. standard of care, where the participant will undergo their usual clinical follow-up 2. exercise therapy, where the participant will receive a personalised 12 week exercise, nutrition and wellbeing programme participants in both study arms will be asked to complete quality of life questionnaires and a basic fitness assessment at the start and end of the study follow-up period. participants will be asked if they would be happy to conduct a short interview with a member of the research team, to assess their views on the study. this interview will be audio recorded and the audio recording will be transcribed anonymously to allow researchers to improve future study design.

the aim of this study is to examine the feasibility of a randomised trial of exercise therapy in mesothelioma. it will define likely rate of recruitment based on performance in two mesothelioma centres and identify barriers to recruitment and retention. outcomes from the study will help refine the design of a future definitive phase 3 trial. that future phase 3 trial will have a patient-centred primary endpoint, e.g. a meaningful improvement in health related quality of life (hrqol) or an increase in treatment uptake or tolerance. additional outcome measures are likely to include functional fitness, hospital admissions and overall survival. a randomised prospective feasibility study will be performed over 12 months in two centres in the united kingdom (glasgow and manchester). if eligible for the study, patients will be randomised 1:1 to receive a personalised exercise programme or standard care. patients randomised to the intervention (exercise) arm will undergo an individualised assessment by either a physiotherapist or a qualified exercise specialist with specialised exercise and health condition qualifications. following this initial assessment, patients will receive a tailored exercise, wellbeing and nutritional support package. the investigators will assess functional fitness and health-related quality of life scores as study outcome measures. the investigators also aim to conduct semi-structured interviews in patients who decline to participate or drop out of the study in order to examine barriers to study recruitment and retention.

Eligibility criteria:
inclusion criteria: 1. diagnosis of mesothelioma, ratified by a mesothelioma multi-disciplinary team (mdt) meeting 2. performance status 0 - 2 3. clinical frailty score ≤5 4. informed written consent exclusion criteria: 1. performance status ≥3 2. clinical frailty score ≥6 3. unlikely to be able to participate in an exercise programme (clinician/physiotherapist judgement)
malaria in strasbourg university hospital

Conditions: Malaria

Summary: the primary purpose is to describe the anamnestic, clinical, biological, and therapeutic characteristics of imported malaria in people originated from endemic areas. indeed, clinicians have observed that people from such areas start malaria just after their arrival in france. such observation needed to be confirmed. in addition, the investigators observed a variation in the laboratory diagnostic performance of malaria between hospital and private laboratories. such observation also needed to be analyzed objectively


Eligibility criteria:
inclusion criteria:- patient over 18 years * patients from birth to 18 years * patient submitted to guardianship * patient submitted to trusteeship * diagnosis patients with malaria from 01/01/2017 to 01/01/2018 * patient or legal representative agree to use medical data for this research exclusion criteria: * lack of confirmation malaria diagnosis * impossibility to inform patients * patient who does not wish to participate in the study * patient submitted to justice safeguarding

Keywords: malaria malaria imported cases recurrent malaria endemic malaria areas biological diagnosis hospital vs private laboratory diagnosis
study of subthalamic brain stimulation in parkinson disease (pd)

Conditions: Parkinson Disease

Summary: deep brain stimulation (dbs) improves debilitating symptoms of movement disorders when conventional medical therapies and novel surgical therapies fail. despite the remarkable efficacy of dbs, its therapeutic mechanism remains unclear. there is controversy regarding whether the therapeutic effects of dbs are associated with inhibition or excitation of target neurons, the introduction of new activity into the network, or a combination of these mechanisms. additionally, it is unclear why stimulus frequency plays an important role in the clinical response to therapy. the fundamental hypothesis of this proposal is that unilateral subthalamic nucleus (stn) dbs in pd alters neuronal activity in the bilateral basal ganglia-thalamic-cortical motor system in a manner that is dependent on stimulation frequency.


Eligibility criteria:
inclusion criteria: * patients with parkinson disease who have undergone subthalamic deep brain stimulation exclusion criteria: * patients who are unable to follow verbal instructions * patients who are unable to tolerate being off their parkinson's medications for 12 hours * patients who are medically unstable
the pharmacokinetic variability of sunitinib in patients with metastatic renal cancer

Conditions: Kidney Neoplasms

Summary: the primary objective of this study is to determine the percentage of patients with a plasma concentration of sunitinib remaining at equilibrium (\[suni\]req) greater than 100 ng / ml (effective concentration according to the current literature).

the secondary objectives of this study are: * to describe the distribution of constitutional genetic determinants related to sunitinib pharmacokinetics, and to study their correlation with * the \[suni\]req, * the advent of toxicity, * the tumor response. * to describe the variation in the \[suni\]req and the plasma concentration of the active entity remaining at equilibrium (\[actent\]req) at: * the interindividual level, * overtime, between chemotherapy cycles. * to describe the variation in the ratio of the plasma concentration of the metabolite remaining at equilibrium (\[metab\]req) to the \[suni\]req at: * the interindividual level, * overtime, between chemotherapy cycles. * to explore potential correlations between the \[suni\]req and * toxicity, * tumor response. * to explore potential correlations between the \[actent\]req and * toxicity, * tumor response. * to explore potential correlations between the ratio \[metab\]req / \[suni\]req and * toxicity, * tumor response.

Eligibility criteria:
inclusion criteria: * the patient was correctly informed concerning the implementation of the study, its objectives, constraints and patient rights * the patient must have given his/her informed and signed consent * the patient must be insured or beneficiary of a health insurance plan * the patient has kidney cancer and should begin treatment with sunitinib (sutent) at the time of inclusion exclusion criteria: * the patient started treatment with sunitinib (sutent) before inclusion * the patient is participating in another interventional study * the patient has participated in another interventional study within the last month * the patient is in an exclusion period determined by a previous study * the patient is under judicial protection, under tutorship or curatorship * the patient refuses to sign the consent * it is impossible to correctly inform the patient * the patient is pregnant, parturient, or breastfeeding * the patient has a contraindication (or an incompatible drug combination) for a treatment used in this study

Keywords: metastatic kidney cancer
routine transcervical thymectomy in men-1 patients

Conditions: Multiple Endocrine Neoplasia Type 1 (MEN-1); Thymic Carcinoid

Summary: a case series was built after review of available literature by searching four databases (pubmed, embase, medline and cochrane library) for observational studies or case reports on routine prophylactic tct for men-1 and the development of thymic carcinoids.

introduction and importance malignant thymic carcinoids are uncommon but important entities among patients with multiple endocrine neoplasia type 1 (men-1). current treatment guidelines advise the performance of a routine transcervical thymectomy (tct) during parathyroidectomy, to prevent its development, although data on the yield of this prophylactic tct is scarce. we aimed to revisit available literature to investigate and summarize the efficacy of routine tct during neck exploration for parathyroidectomy, for the prevention of thymic carcinoid tumours among men-1 patients. methods a case series was built after review of available literature by searching four databases (pubmed, embase, medline and cochrane library) for observational studies or case reports on routine prophylactic tct for men-1 and the development of thymic carcinoids.

Eligibility criteria:
inclusion criteria: * studies including men-1 patients who underwent a routine thymectomy during parathyoidectomy * we accepted randomized controlled trials or observational studies that included patients of any age who underwent a routine tct in the setting for men-1, published as full-length articles in peer-reviewed journals, which mentioned data on thymic carcinoid tumours. exclusion criteria: * we excluded reviews, letters, conference proceedings and non-english publications.

Keywords: routine transcervical thymectomy
the effect of upper extremity telerehabilitation on balance and gait

Conditions: Parkinson Disease

Summary: parkinson's disease (pd) is a disease that affects the upper extremity functional skills with clinical findings such as bradykinesia, rigidity, and hypokinesia and causes limitations in the daily living activities of the patients. the influence of fine dexterity, reaching, and grasping movements greatly affects the daily living activities of the patients. medical treatment and surgical approaches are frequently used among the treatment options for pd today. physiotherapy and rehabilitation approaches for progressive functional loss in pd, together with optimal medical and surgical treatment, form the basis of pd treatment. recently, it has been stated that intensive and task-specific rehabilitation interventions in the field of physiotherapy and rehabilitation will be more effective than traditional rehabilitation approaches. on the other hand, telerehabilitation approaches, the use of which has increased rapidly due to technological developments in recent times, enables the delivery of rehabilitation services to patients in distant places by using communication technologies. for this purpose, it is highly valuable to implement a task-oriented training (tot) program based on motor learning-based principles, which consists of intense exercise content, through telerehabilitation. although there are very few studies investigating the effectiveness of telerehabilitation-based tot in pd, these studies have shown that upper extremity motor performance, activities of daily living, and quality of life are improved. on the other hand, no study has been found showing the effect of upper extremity tot applied through telerehabilitation on balance and walking. therefore, there is a need to investigate the effectiveness of telerehabilitation-based tot exercises on balance and walking.

this study is a randomized controlled study. the patients will be randomly divided into two groups exercise and control. balance and walking exercises consisting of 3 days a week for 6 weeks will be given to both groups as a home program. in addition, the exercise group will receive task-oriented training (tot) based telerehabilitation via video conferencing 3 days a week for 6 weeks. tot will be formed from daily life activities such as reaching out, grasping, writing, and manual skills, which are frequently used in daily life. as the outcome measures, disease severity, and disability, balance, and gait will be evaluated.

Eligibility criteria:
inclusion criteria: * 40- 80 years of age * having diagnosed with "parkinson's disease" by a specialist physician * having between 1-3 stages according to the hoehn and yahr scale * mini-mental test score more than or equal 24 exclusion criteria: - any orthopedic, vision, hearing, cardiovascular, or perception problems that may affect the research results

Keywords: parkinson disease task oriented training balance gait
safety and efficacy of allo-501a anti-cd19 allogeneic car t cells in adults with relapsed/refractory large b cell lymphoma, chronic lymphocytic leukemia and small lymphocytic lymphoma (alpha2)

Conditions: Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma

Summary: this is a single-arm, open label, multicenter phase 1/2 study evaluating allo-501a in adult subjects with r/r lbcl and cll/sll. the purpose of the alpha2 study is to assess the safety, efficacy, and cell kinetics of allo-501a in adults with relapsed or refractory large b-cell lymphoma and assess the safety of allo-501a in adults with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (cll/sll) after a lymphodepletion regimen comprising fludarabine, cyclophosphamide, and allo-647.


Eligibility criteria:
inclusion criteria: for subjects with lbcl: * histologically confirmed diagnosis of relapsed/refractory large b-cell lymphoma at last relapse per who 2017 * at least 1 measurable lesion at time of enrollment * relapsed or refractory disease after at least 2 lines of chemotherapy * absence of significant donor (product)-specific anti-hla antibodies (dsa) at screening (note: only applicable for phase 2) for subjects with cll/sll: * diagnosis of cll/sll * relapsed/refractory disease * subjects relapsed/refractory to btki therapy and high-risk disease * subjects relapsed/refractory with 2 or more lines of therapy including btki and bcl-2 inhibitor (venetoclax) * at least 1 measurable lesion at time of enrollment for all subjects: * male or female subjects ≥18 years of age * eastern cooperative oncology group (ecog) performance status (ps) of 0 or 1 * adequate hematological, renal, and liver function exclusion criteria: * active central nervous system (cns) involvement by malignancy * current thyroid disorder (including hyperthyroidism), except for subjects with hypothyroidism controlled on a stable dose of hormone replacement therapy * any other active malignancies that required systemic treatment within 3 years prior to enrollment * radiation therapy within 2 weeks prior to allo-647 * prior irradiation to \>25% of the bone marrow * hypocellular bone marrow for age by institutional standard as determined from a bone marrow biopsy performed at time of screening (note: only applicable for phase 2). * autologous hematopoietic stem cell transplant (hsct) within last 6 months (24 weeks) * systemic anti-cancer therapy within 2 weeks prior to receiving allo-647

Keywords: car t cell therapy allogeneic cell therapy cellular immuno-therapy allocar t allo-501a allo-647 lbcl lymphoma large b-cell lymphoma cema-cel cemacabtagene ansegedleucel leukemia chronic lymphocytic leukemia cll small lymphocytic lymphoma sll
feasibility of breast cancer risk evaluation in women from the general population

Conditions: Breastcancer

Summary: this study aims to evaluate the feasibility (acceptability) of a consultation dedicated to informing women about their risk of breast cancer and the screening methods recommended for them according to the recommendations in force during a routine consultation at a general practitioner, a gynecologist or a radiologist.


Eligibility criteria:
inclusion criteria: * woman from 40 to 74 years old * understanding the french language exclusion criteria: women will not be eligible for study if they are in any of the following situations: * cancer active or in the course of treatment type surgery, chemotherapy, or radiotherapy, whether breast or other organ * recent diagnosis \<1 year of suspicious or cancerous lesions * psychiatric pathology not compatible with the study * poor understanding of the french language
smart kneebrace for continuous monitoring of joint angles during rehabilitation

Conditions: Arthroplasty, Replacement, Knee; Knee Osteoarthritis

Summary: this study aims to investigate the effect of smart kneebrace use for osteoarthritis patients after total knee arhtroplasty (tka) on post-operative performance.

this is a single-center, open-label randomized controlled clinical trail. a total of 60 participants will receive total knee arthroplasty, who will be randomly assigned into experiment or control group. smart kneebrace will be used for the patients during the rehabilitation for the patients in experiment group, while the patients in the control group will not receive such a smart kneebrace. postoperative joint angles as well as visual analog scale pain score, the western ontario and mcmaster universities osteoarthritis index knee society score will be estimated before operation and at 6/12 weeks after operation.

Eligibility criteria:
inclusion criteria: * ready to receive single-side tka exclusion criteria: * contraindication of surgery * self-reported diseases that cause lower limb disability (for example, cerebrovascular disease especially stroke)

Keywords: total knee arthroplasty rehabilitation smart kneebrace
a study of resveratrol as treatment for friedreich ataxia

Conditions: Friedreich Ataxia

Summary: the purpose of this study is to determine the effect of two doses of resveratrol taken for a 12 week period, on frataxin levels in individuals with friedreich ataxia. this study will also measure the effect of resveratrol on markers of oxidative stress, clinical measures of ataxia, and cardiac parameters.

resveratrol shows promise as an agent for the treatment of friedreich ataxia due to its antioxidant properties, neuroprotective effects, and ability to increase frataxin levels in vitro and in vivo. this clinical pilot study aims to determine the effect of two doses of resveratrol (1g/day and 5g/day) taken for 12 weeks, on frataxin levels in individuals with friedreich ataxia. additional outcome measures include the effect of resveratrol on markers of oxidative stress, clinical measures of ataxia , and cardiac parameters (including relative wall thickness and left ventricular mass index).

Eligibility criteria:
inclusion criteria: * adults with friedreich ataxia due to homozygosity for the gaa repeat expansion in intron 1 of the fxn gene * functional stage on the ataxia subscale of the fars of 1 or higher exclusion criteria: * women who are pregnant or lactating * active arrythmias or significant cardiac insufficiency * use of idebenone, coenzyme q or vitamin e within 30 days prior to enrolment * use of amiodarone or other medications which may have clinically significant drug interactions that cannot be safely monitored

Keywords: friedreich ataxia resveratrol frataxin cardiomyopathy oxidative stress
covered versus uncovered biliary stents for biliary malignancies

Conditions: Biliary Tract Cancer

Summary: patency duration of covered metal stents as compared with uncovered metal stents in the management of malignant strictures of the extra-hepatic biliary tree.

consecutive patients with malignant strictures of the extra-hepatic biliary tree considered unfit for surgical excision placement of covered or uncovered metal stents in patients with and without gallbladder on the basis of a computer-generated randomization list evaluation of clinical outcome, survival, complications, and quality of life. evaluation of the cost and efficacy of the two types of metal stents.

Eligibility criteria:
inclusion criteria: * adult patients with symptomatic malignant obstruction of the extra-hepatic biliary tree * not eligible for surgical intervention * able to provide informed consent exclusion criteria: * benign biliary obstruction * previous surgery of the biliary tract * life expectancy \< 3 months

Keywords: distal malignancy of the extra-hepatic biliary tract metallic biliary stents covered biliary stents uncovered biliary stents
breast re-irradiation after second ipsilateral lumpectomy

Conditions: Breast Cancer; Cancer; Cancer of the Breast; HER2-negative Breast Cancer; ER+ Breast Cancer; Estrogen-receptor-positive Breast Cancer

Summary: the purpose of this research study is to test the safety and possible harms of treating breast cancer with reirradiation, after breast surgery. the researchers want to find out what effects (good and bad) reirradiation has on people who have already received radiation before surgery.


Eligibility criteria:
inclusion criteria: * diagnosed with er+her2- breast cancer * provision of signed and dated icf * stated willingness to comply with all study procedures and availability for the duration of the study * age ≥ 40 years * oncotype \< 26 (postmenopausal) \<16 (premenopausal), low, or ultra-low index. * minimum interval of 18 months from last breast radiotherapy session. * prior radiation therapy in the form of brachytherapy, external beam mv photons, protons or intraoperative radiation are allowed with an upper total dose limit of 68 gy (eqd2) for those patients with prior records available. * ipsilateral recurrence, unifocal \< 3 cm with negative margins, n0, tis and invasive (pathological staging) * eastern cooperative oncology group (ecog) ≤ 2 * planning target volume: whole breast (ptv: wb) ratio \< 1/2 * life expectancy \> 12 months * individuals able to become pregnant: agreement to use highly effective contraception starting at screening through treatment, and for 1 year after the end of pbi. should a participant become pregnant or suspect that they are pregnant while participating in this study, they should notify the treating physician immediately. a person able to become pregnant is any person assigned female at birth (regardless of gender identity, sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria: 1. has not undergone a hysterectomy or bilateral oophorectomy; or 2. has not been naturally postmenopausal for at least 12 consecutive months (i.e., has not had menses at any time during the preceding 12 consecutive months) exclusion criteria: * brca1/2 mutation or any other receptor subtypes * individuals assigned male at birth with breast cancer * pregnancy or breastfeeding * skin involvement * distant metastasis * patients with initial high-risk triple negative or her-2 enriched breast cancer will be excluded from the trial. however, if the initial subtype is not known, patients will still be allowed to enroll, and the initial primary tumor information will be recorded as missing on the clinical forms. * other malignancies (except skin) * connective tissue disorder (e.g., scleroderma, lupus) * any other condition that may put a participant at higher risk, at the discretion of the investigator.
program of exercise, diet and control of psychological stress in cancer survivors

Conditions: Cancer Survivors

Summary: a program of exercise, diet and psycho-emotional support could improve some outcomes in cancer survivors.

cancer survivors will be randomised to one of the following groups: a) supervised physical activity, b) supervised physical activity + diet counseling, c) supervised physical activity + diet counseling + psycho-emotional support

Eligibility criteria:
inclusion criteria: * cancer survivors attending their follow-up visits exclusion criteria: * cardiac disease nyha ii * non-controlled hypertension * non-controlled metabolic disease * chronic infectious disease * non-controlled pain * risk of bone fracture * severe anemia, leucopenia or thrombopenia

Keywords: cancer survivors, exercise, diet, emotional support